Loading...
•
Jun 30, 2024
NeueHealth Q2 2024 Earnings Report
Reported solid Q2 2024 results, driven by focus on value-driven model and high-quality care, with positive Adjusted EBITDA for the second consecutive quarter.
Key Takeaways
NeueHealth reported solid Q2 2024 results with positive Adjusted EBITDA for the second consecutive quarter. The company is reaffirming Adjusted EBITDA guidance for the full year and expects to reach the high end of the guidance range for consumers served by year-end.
Drove solid Q2 ‘24 results with continued focus on advancing value-driven model
Delivered high-quality, consumer-centric care to all populations across the ACA Marketplace, Medicare, and Medicaid
Delivered positive Adjusted EBITDA for the second consecutive quarter in 2024; reaffirming Adjusted EBITDA guidance for the full year
Positioned for continued strong performance this year and beyond, expecting to reach high end of guidance range for consumers served by year-end
Forward Guidance
For 2024, NeueHealth expects revenue to be approximately $950 million, with NeueCare revenue around $320 million and NeueSolutions revenue around $640 million. The adjusted operating cost ratio is projected to be between 15% and 16% excluding corporate costs, and between 19% and 20% including corporate costs. Adjusted EBITDA is expected to be between $15 million and $25 million.
Positive Outlook
- Revenue is expected to be approximately $950 million
- NeueCare Revenue is expected to be approximately $320 million
- NeueSolutions Revenue is expected to be approximately $640 million
- Adjusted Operating Cost Ratio is expected to be between 15% and 16%, excluding corporate costs
- Adjusted EBITDA is expected to be between $15 million and $25 million in 2024
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...